The dopamine system may be involved in three situations: the nigral projection to the basal ganglia, the mesocortical projection to the anterior cingulate gyms, or the medial forebrain bundle projection to cortical and limbic sites. Because of the close association of dopaminesystems with the knownneurological syndromes of akinesia, we elected to treat a patient with akinesia due to rupture of anterior communicating artery (ACA) aneurysm with the dopamine agonist, bromocriptine. This case has important implications for the understanding of brain/behavior relationships as well as for the development of new therapies for patients who have sustained neurological injury.
Dopamine is a neurotransmitter that has long been known to affect motor system function through the nigrostriatal pathway (1) . Dopamine also influences other neurological systems. Through its effect on limbic system function, for example, dopamine has been implicated in the expression of psychotic (2) and affective (3) symptoms. Albert et al (4) and Bachman and Morgan (5) recently suggested that damage to mesocortical dopamine systems maybe responsible for certain features of aphasia and have demonstrated that the dopamine agonist, bromocriptine, may effectively alleviate selected aphasic symptoms. Akinesia mayoccur as the result of lesions of the basal ganglia or nigrostriatal system, as in Parkinson's disease, lesions of the anterior cingulate region (6, 7), pressure on the walls of the third ventricle secondary to tumor (8), or lesions of the midbrain/ diencephalic junction (9). The dopamine system may be involved in all three situations: the nigral projection to the basal ganglia, the mesocortical projection to the anterior cingulate gyms, or the medial forebrain bundle projection to cortical and limbic sites. Because of the close association of dopamine systems with the known neurological syndromes of akinesia, we elected to treat a patient with akinesia due to rupture of an anterior communicating artery (ACA) aneurysm with the dopamine agonist, bromocriptine. He wasunable to cooperate with testing for more than 15 to 20 min and even then required frequent prompts and cues. Responsestyle was notable for long latencies with minimal responses. In addition, he frequently had difficulty in initiative responses.
REPORT OF A CASE
He had no appreciation of his situation and at times confabulated that he was at work. Distractability, pull to stimulus, and perseveration characterized all task performances. Utterances were grammatical but monotonous and laconic. There was no evidence of impaired confrontational naming or auditory comprehension. Visuospatial function was intact for copying except for pull to stimulus and perseveration. He could carry out 1 and 2 step commands but refused to perform morecomplexcommands. A trial of bromocriptine was instituted. Bromocriptine was begun at a dose of 2.5 mg a day and was gradually adjusted upwards to a total daily dose of 15 mg a day over 10 days. No significant side effects were encountered. During treatment there was a marked change in the patient's overall behavior. He now frequently initiated conversation and would develop a lengthy reply in response to questions. Movements were quicker and a more normal facial affect was apparent. Onthe Boston Naming Test (10) there was a slight improvement in the overall score with a significant decrease in perseverations and response latencies. Unfortunately, he remained extremely amnestic and inattentive. Spontaneous initiation of confusional behavior on the ward became disruptive. Whenthe bromocriptine was gradually discontinued, his initiation of movement and speech was slightly worse but disruptive behaviors continued for a number of weeks afterwards. These behaviors also gradually abated. 
DISCUSSION

